Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The TAS1R2/TAS1R3 Sweet Taste Receptor is a heterodimeric G protein-coupled receptor (GPCR) that serves as the primary sensor for sweet-tasting molecules, including sugars, polyols, and high-intensity sweeteners (UniProt: P59768, Q7RTX0). Beyond its well-known role in the oral cavity for taste perception, this receptor is expressed in various extra-oral tissues, including the gut, pancreas, and hypothalamus, where it acts as a nutrient sensor (PubMed: 21414488). In the gastrointestinal tract, activation of TAS1R2/TAS1R3 by luminal glucose triggers the release of incretin hormones such as glucagon-like peptide-1 (GLP-1), which modulates insulin secretion and gastric emptying (PubMed: 17709750). Because of its central role in glucose homeostasis and energy balance, the receptor is a significant focus in research regarding obesity and type 2 diabetes (PubMed: 28533247). Pharmacological agents interacting with this receptor include a wide range of commercial sweeteners as agonists and compounds like lactisole or gymnemic acids as antagonists (PubChem: CID 109557). Understanding the systemic effects of TAS1R2/TAS1R3 activation is essential for evaluating the metabolic impact of non-nutritive sweeteners and developing novel therapeutic strategies for metabolic syndrome. The receptor's ability to detect diverse chemical structures makes it a unique target for both food science and metabolic pharmacology.
The receptor functions as a heterodimer that, upon binding sweet ligands, activates a G protein signaling cascade involving G-alpha-gustducin or G-alpha-q, leading to the activation of phospholipase C beta 2 (PLC-beta-2) and the opening of TRPM5 ion channels, resulting in cell depolarization and neurotransmitter or hormone release (PubMed: 11830529).
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Taste receptor type 1 member 2 and Taste receptor type 1 member 3 heterodimer (TAS1R2/TAS1R3).